Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX208 in Advanced BRAF V600 Mutated NSCLC
NCT05065398Phase 2Unknown
- Sponsor
- Henlius
- Start
- Nov 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HLX208 in non-small cell lung cancer (NSCLC), sponsored by Henlius. Status: unknown.
02
Drugs
HLX208
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05065398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05065398.